Shares of top-German, pharmaceutical and chemical giant, Bayer AG (BAYN.DE) fell today the most since March, as Washington state court will review a case alleging potentially toxic chemicals from the Monsanto, Bayer unit (completed acquisition in 2018). In such case, three teachers claim that, Monsanto product caused brain injuries.
The court denied an application for a 'speedy' review of this case. According to Bloomberg Intelligence report, Bayer’s exposure to the Roundup litigation (another Monsanto's product) could exceed the Bayer's almosta $16 billion reserve by around 5%. German company has more than 57k unfinished cases related to Roundup; still claiming that Roundup is totally safe.
Bayer AG (BAYN.DE, D1 interval)
As we can see below, Bayer shares failed to break above resistance of the EMA200 (red line) and now are falling back to levels unseen since half-September.
Source: xStation5
US OPEN: All-time high and expectations ahead of the Fed
What can we expect from Meta's Q4 2025 results? Advertising, AI, and the price of aggressive growth
Starbucks gains after Q4 earnings amid turnaround in the US market📈
US500 at all-time high ahead of the Fed🗽Will BigTech support the momentum?